Monthly Prescribing Reference9h
STEP UP Trial: Significant Weight Loss Observed With Higher Dose Semaglutide
The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...